Bone marrow-derived stem cells for treatment of ischemic cardiomyopathy

The aim of this study was to compare the potential of bone marrow-derived mononuclear cells versus that of bone marrow-derived mesenchymal stem cells to treat ischemic cardiomyopathy and also to assesm a new route of cell delivery via a helical catheter. The study demonstrates that transcatheter, intramyocardial injection of autologous bone marrow preparations in patients with chronic ischemic cardiomyopathy is well tolerated and achieves functional recovery in scarred myocardium and reverse remodeling of the left ventricular chamber.